Now is a really good time to focus on carbapenem-resistant bacteria. We have spent much of the past 3 years focusing on one particular virus. But now that the clinical issues linked to SARS-CoV-2 are waning for our hospital patients, the threat of carbapenem-resistance in Gram-negative bacteria comes to the fore. An excellent study with far-reaching consequences has been published from Italy. Carbapenem resistance is bad news if you have a BSI: patients with carbapenem-resistant BSI were roughly twice as likely to die as patients with carbepenem-susceptible BSI.